14:00 - 15:30
主持人 Moderator
- 李小英, 复旦大学附属中山医院内分泌科教授
- LI Xiaoying, Director of Department of Endocrinology, Zhongshan HospitalFudan University
14:00 - 14:30
- 主题报告1
- Keynote Speech 1
- 以临床需求为导向的肥胖药物开发
- Clinical Needs-Driven Drug Development for Obesity
- 纪立农, 北京大学人民医院内分泌科主任
- JI Linong, Director of Endocrinology and Metabolism Department, Peking University People's Hospital
14:30 - 15:00
- 主题报告2
- Keynote Speech 2
- ActRII药物在增肌减脂领域的研发进展
- Targeting ActRII for Muscle Preservation and Fat Reduction in Obesity
- 王俊, 来凯医药有限公司副总裁,临床开发负责人
- Gary WANG, VP, Head of Clinical Development, Laekna
15:00 - 15:30
- 主题报告3
- Keynote Speech 3
- 超长效减重药物开发策略
- Development of Ultra-Long-Acting Anti-Obesity Medications
- 张媛媛, 北京质肽生物医药科技有限公司联合创始人,R&D高级副总裁
- ZHANG Yuanyuan, Cofounder, R&D SVP of Beijing QL Biopharmaceutical Co., Ltd.
15:30 - 16:30
主持人 Moderator
- 康韦, RDPAC 前执行总裁,粤港澳大湾区医药创新联合会发起人
- KANG Wei, Former RDPAC Managing
15:30 - 16:00
- 主题报告4
- Keynote Speech 4
- 减重药物开发布局与趋势
- Overview of Weight Loss Drug Development Landscape
- 陈虹, 江苏恒瑞医药股份有限公司临床研发医学高级总监
- CHEN Hong, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Senior Director
16:00 - 16:30
- 主题报告5
- Keynote Speech 5
- 减重药物创新研发的思考
- Reflections on the Innovative Research and Development of Anti-Obesity Medicines
- 程坚, 礼来公司高级医学总监
- CHENG Jian, Senior Medical Director of Eli Lilly & Company
16:30 - 17:10
- 主题讨论
- Panel
- 突围减重赛道:差异化竞争、支付瓶颈与临床价值回归
- How to Navigate the Anti-Obesity Drug Development Space
主持人 Moderator
- 纪立农, 北京大学人民医院内分泌科主任
- JI Linong, Director of Endocrinology and Metabolism Department, Peking University People's Hospital
讨论嘉宾:
Panelist:
- 李小英, 复旦大学附属中山医院内分泌科教授
- LI Xiaoying, Director of Department of Endocrinology, Zhongshan HospitalFudan University
- 郭武栋, 国家卫生健康委卫生发展研究中心研究员
- GUO Wudong, Researcher of China National Health Development Research Center
- 唐文熙, 中国药科大学国际医药商学院教授
- TANG Wenxi, Director of the Clinical Pharmacy Department, The First Affiliated Hospital, Zhejiang University School of Medicine
- 林亮, 礼来亚洲基金合伙人
- LIN Liang, Partner, LAV
- 王庆华, 银诺医药董事长兼首席执行官
- WANG Qinghua, INNOGEN Chairman and CEO
- 钱镭, 信达制药集团首席研发官(综合产品线)
- QIAN Lei, Chief R&D Officer, Innoventbio